Table 1 Clinicopathological characteristics of the breast carcinoma study population
Clinicopathological characteristics | Frequency | Frequency (Valid percentage %) |
|---|---|---|
Age (Years) | ||
Mean age (SD) | 57.36 (SD 11.96) | |
Age category | ||
< 40 years | 38 | 9% |
41 – 70 years | 328 | 78% |
> 71 years | 54 | 13% |
Histological subtypes of tumours | ||
Invasive carcinoma, NST | 374 | 89% |
Lobular carcinoma | 9 | 2.1% |
Mucinous carcinoma | 10 | 2.4% |
Tubular carcinoma | 1 | 0.2% |
Invasive breast carcinoma with medullary pattern | 5 | 1.2% |
Invasive papillary carcinoma | 1 | 0.2% |
Invasive cribriform carcinoma | 2 | 0.5% |
Metaplastic carcinoma | 1 | 0.2% |
Micropapillary carcinoma | 3 | 0.7% |
Adenoid cystic carcinoma | 2 | 0.5% |
Pleomorphic lobular carcinoma | 7 | 1.7% |
Solid papillary carcinoma | 3 | 0.7% |
Tubulolobular carcinoma | 1 | 0.2% |
Mixed carcinoma (Mucinous + Ductal) | 1 | 0.2% |
Nottingham grade | ||
Grade 1 | 32 | 7.6% |
Grade 2 | 150 | 35.7% |
Grade 3 | 238 | 56.7% |
Hormone receptor status and HER 2 Overexpression | ||
Oestrogen receptor status | ||
Positive | 323 | 76.9% |
Negative | 97 | 23.1% |
Progesterone receptor status | ||
Positive | 308 | 73.3% |
Negative | 112 | 26.7% |
HER 2 Overexpression | ||
0/1 + (Negative) | 280 | 66.7% |
3 + (Positive) | 140 | 33.3% |
Surrogate molecular subtype | ||
Luminal like | 323 | 76.7% |
HER 2 Positive (Non luminal) | 44 | 10.5% |
Triple negative | 54 | 12.9% |